Cadila Healthcare rose 1.22% to Rs 339.60 at 14:20 IST on BSE after the company received tentative approval from the USFDA to market Clofarabine Injection 20mg/20ml vials in the US.
The announcement was made during market hours today, 9 March 2016.
Meanwhile, the BSE Sensex was up 50.55 points, or 0.2%, to 24,709.78.
On BSE, so far 92,956 shares were traded in the counter, compared with an average volume of 2.64 lakh shares in the past one quarter. The stock hit a high of Rs 341.80 and a low of Rs 331.50 so far during the day. The stock hit a record high of Rs 454.40 on 23 October 2015. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past one month till 8 March 2016, rising 2.47% compared with gains of 1.53% in the Sensex. The scrip had, however, underperformed the market in past one quarter, sliding 14.77% as against Sensex's 2.57% fall.
The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Re 1.
Cadila Healthcare's consolidated net profit rose 38.2% to Rs 389.60 crore on 8.1% growth in net sales to Rs 2341.80 crore in Q3 December 2015 over Q3 December 2014.
More From This Section
Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News